BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.52
arrow_downward
-0.58%(-0.050) 1D
$8.43
arrow_downward
-1.00% (-0.085)bedtimeAfter hours
Closed: Sep 24, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$8.54
High
$8.65
Low
$8.40
Mkt. cap
2.18B
Avg. vol.
4.07M
Volume
4.85M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
Open
$8.54
High
$8.65
Low
$8.40
Mkt. cap
2.18B
Avg. vol.
4.07M
Volume
4.85M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
Simply Wall Street
·
16 hours ago
Will Japan Pediatric Approval Change BioCryst Pharmaceuticals (BCRX) Narrative
Yahoo Finance
·
1 day ago
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com